Imagine a smart garment that acts like a 24/7 security guard for your veins. It uses tiny ultrasound and light sensors to spot blood clots in the legs before they cause a dangerous lung blockage. It even uses games and virtual reality to help patients stay active and prevent clots from forming in the first place.
DVT is often 'silent,' meaning 2/3 of cases show no symptoms until a life-threatening pulmonary embolism occurs. Current ultrasound and plethysmography methods are not suitable for continuous, operator-free monitoring at the point of care.
A wearable diagnostic device combining ultrasound hardware, impedance plethysmography, and light reflection rheography. It includes an AI-driven decision support unit, serious games for prevention, and XR guidance for users.
If you are a wearable health tech developer dealing with the lack of continuous blood clot monitoring — this project developed a device combining ultrasound, impedance plethysmography, and light reflection rheography that enables operator-free detection of DVT.
If you are a post-surgical care center dealing with silent DVT episodes in bedridden patients — this project developed an AI-driven monitoring system that provides accurate alerts and risk estimation for postoperative patients in the ward.
If you are a health app developer dealing with low patient compliance in recovery exercises — this project developed serious gaming and extended reality tools that guide patients to use the device optimally and prevent DVT.
Based on available project data, there is no information regarding the unit cost or pricing model for the device.
The project includes 9 industrial partners and 6 SMEs, suggesting a strong focus on industrial scalability and manufacturing readiness.
Based on available project data, specific IP or licensing terms are not disclosed, though the consortium includes a mix of research centers and industry partners.
The project includes regulatory experts and plans to validate the outcome via 3 large scale clinical studies, 1 early feasibility study, and 1 multi-center clinical trial.
The project period runs from 2024-01-01 to 2027-06-30, indicating that validation and testing will continue through mid-2027.
The system uses an intelligence decision support unit to aggregate data and provide alerts, though specific software integration protocols are not detailed.
The consortium is heavily weighted toward commercialization, with a 50% industry ratio (9 industrial partners, including 6 SMEs). This balance between 3 universities, 4 research centers, and 9 industry players across 8 countries suggests a high priority on translating the AI and wearable hardware into a viable commercial product.
Contact ATHINA-EREVNITIKO KENTRO KAINOTOMIAS for partnership or licensing inquiries.
Contact us to connect with the ThrombUS+ consortium for early adoption opportunities.
